Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)
Sponsor: Seagen Inc.
A NA clinical study on Hodgkin Lymphoma, Adult, this trial is completed. The trial is conducted by Seagen Inc. and has accumulated 12 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
▶ Show 7 earlier versions
-
Mar 2020 — Nov 2020 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Mar 2020 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Mar 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seagen Inc.
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .